Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
Eli Lilly & Co. (LLY) sees volatility amid Novo's warning
February 3, 2026 11:46 AM ESTEli Lilly & Co. (NYSE: LLY) stock is volatile following weak guidance from rival Novo Nordisk (NYSE: NVO)
Novo Nordisk's fourth-quarter performance showed a 2% decline in sales and 4% decrease in operating profit at constant exchange rates. Sales in US Operations... MoreNovo Nordisk reports 2025 sales growth, cuts 2026 outlook
February 3, 2026 11:38 AM ESTNovo Nordisk reported 2025 sales growth of 10% and operating profit growth of 6% at constant exchange rates, according to a company statement. The results exceeded the Danish pharmaceutical company's previous guidance of 8% to 11% sales growth and 4% to 7% operating profit growth.
The company's fourth-quarter performance showed a 2% decline in sales and 4% decrease in operating profit at constant exchange... More
Novo Nordisk (NVO) Halted, News Pending
February 3, 2026 11:36 AM ESTNovo Nordisk (NYSE: NVO) Halted, News Pending
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO)
February 3, 2026 9:33 AM ESTTD Cowen analyst Michael Nedelcovych reiterated a Buy rating and $70.00 price target on Novo Nordisk (NYSE: NVO).
The analyst commented: "CagriSema First Phase III T2D Readout: Solid, But Similar To Mounjaro; Novo reported topline results for Phase III REIMAGINE 2, testing CagriSema in T2D with metformin +/- SGLT2i. At... More
